Trial · NCT05560399
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399, Early phase 1, Active not recruiting, Icahn School of Medicine at Mount Sinai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma. Trials, record NCT05560399. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05560399
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- NCT number
- NCT05560399
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 7 participants, estimated
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Elotuzumab, Dexamethasone
- First posted
- 2022-09-29
- Last updated
- 2026-01-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Iberdomide dose limiting toxicity | 28 days | The dose limiting toxicity (DLT) rate at the Maximum Tolerated Dose, defined as the proportion of patients in the safety population of the study that experience at least 1 DLT within the first cycle of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone treated at the maximum tolerated dose (MTD). |
| Secondary | Overall Response Rate (ORR) | up to 3 months | Overall Response Rate (ORR) is defined as the proportion of patients treated at the MTD of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in both phase 1 and DEC phase of the study that achieved best overall response of PR or better (Stringent Complete Response (sCR); Complete Response (CR); Very good partial response (VGPR); Partial Response (PR), according to International Myeloma Working Group (IMWG) criteria at Cycle 4 Day 1 (C4D1). |
| Secondary | Number of adverse events (AE) | up to 3 months | Number of Adverse Events (AE) - an AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure |
| Secondary | Progression-free survival (PFS) | up to 3 months | PFS: is defined as the duration of time from start of treatment to the first occurrence of disease progression or death on study from any cause, whichever occurs earlier |
| Secondary | Best Overall Response Rate (BOR) | up to 3 months | Best Overall Response Rate (BOR) is defined as the proportion of patients treated at the MTD of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in both phase 1 and DEC phase of the study that achieved sCR, CR, VGPR, PR, minimal response, and Stable Disease (SD), according to IMWG criteria at any evaluation assessment prior to progression of disease as their best response. |
| Secondary | Duration of Response (DOR) | up to 3 months | Duration of Response (DOR) is defined as the time from achieving a PR or better to progression, per 2016 IMWG criteria |
| Secondary | Overall Survival (OS) | up to 3 months | Overall survival is defined from time from initiation of treatment to death by any cause |
| Secondary | Clinical Benefit Rate | up to 3 months | Clinical Benefit Rate is the proportion of patients treated at the MTD of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in both phase 1 and DEC phase of the study that achieved best overall response of minimal response or better (sCR + CR + VGPR + PR + minimal response \[MR\]) according to the IMWG criteria at C4D1 |
| Secondary | Disease Control Rate | up to 3 months | Disease Control Rate is the proportion of patients treated at the MTD of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in both phase 1 and DEC phase of the study that achieved best overall response of stable disease or better (sCR + CR + VGPR + PR + MR + SD) according to the IMWG criteria at C4D1 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05560399
GET https://conductscience.org/api/trials/v1/NCT05560399/registered